Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Assessing the combined effects of oncolytic viruses expressing checkpoint inhibitors and carboplatin on murine melanoma

EF 2024-25

Résumé
Melanoma is an aggressive and malignant type of cancer that arises in the skin. It can often develop in other areas such as the brain or the gastrointestinal tract, making it harder to treat. Treatment methods usually include a mixture of chemotherapy, surgeries, and immunotherapies. Previous research has demonstrated cancer reduction using a type of immunotherapy called immunological checkpoint inhibitors. Normally, checkpoint proteins are present on normal cells and show the immune system that they are healthy. Melanoma cells are also able to present these checkpoints, which helps them evade the immune system. Checkpoint inhibitors are antibodies that block these checkpoints, helping the immune system recognize and kill cancer cells. That being said, the antibodies can also attach to healthy cells, which makes the immune system recognize them as foreign and kill them. Previous studies have shown the use of oncolytic viruses (preferentially attack cancer cells) to infect cancer cells and express the checkpoint inhibitor antibodies locally. This minimizes the risk to other tissues and focuses immune system efforts on the tumour. This novel study builds on the previous research to investigate the effectiveness of chemotherapy combined with oncolytic viruses expressing checkpoint inhibitors in mice. This study will assess tumour growth, mouse survival, the state of the tumour, and the presence of checkpoint inhibitors in non-tumour tissues. This study will be more clinically relevant because combination therapies are much more common and chemotherapy is widely used in these treatments. The results could indicate if this method is a viable and safe treatment for people suffering from this horrible disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529759
Name
Gauthier Luc E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessing the combined effects of oncolytic viruses expressing checkpoint inhibitors and carboplatin on murine melanoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Carboplatin; Checkpoint Inhibitors; Chemotherapy; Ctla-4; Melanoma; Oncolytic Virus; Pd-1; T Cells; Treg; Tumour
Abstract
Melanoma is an aggressive and malignant type of cancer that arises in the skin. It can often develop in other areas such as the brain or the gastrointestinal tract, making it harder to treat. Treatment methods usually include a mixture of chemotherapy, surgeries, and immunotherapies. Previous research has demonstrated cancer reduction using a type of immunotherapy called immunological checkpoint inhibitors. Normally, checkpoint proteins are present on normal cells and show the immune system that they are healthy. Melanoma cells are also able to present these checkpoints, which helps them evade the immune system. Checkpoint inhibitors are antibodies that block these checkpoints, helping the immune system recognize and kill cancer cells. That being said, the antibodies can also attach to healthy cells, which makes the immune system recognize them as foreign and kill them. Previous studies have shown the use of oncolytic viruses (preferentially attack cancer cells) to infect cancer cells and express the checkpoint inhibitor antibodies locally. This minimizes the risk to other tissues and focuses immune system efforts on the tumour. This novel study builds on the previous research to investigate the effectiveness of chemotherapy combined with oncolytic viruses expressing checkpoint inhibitors in mice. This study will assess tumour growth, mouse survival, the state of the tumour, and the presence of checkpoint inhibitors in non-tumour tissues. This study will be more clinically relevant because combination therapies are much more common and chemotherapy is widely used in these treatments. The results could indicate if this method is a viable and safe treatment for people suffering from this horrible disease.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gauthier, Luc E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~